The United States Patent and Trademark Office has issued a fourth U.S. Patent — No. 10,688,147 — incorporating ALASTIN Skincare Inc‘s platform TriHex Technology, the company announces.
The patent is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum with TriHex Technology.
“We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations, which is confirmed by its numerous patents. INhance Post-Injection Serum combines the antiaging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state-of-the-art post-procedure recovery and skin-enhancing benefits.”
— Dr Alan Widgerow, MBBCh (MD); MMed (MHS); FCS; FACS and Chief Medical Officer at ALASTIN
[Source(s): ALASTIN Skincare Inc, PR Newswire]